Seelos Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 1.99
Market capitalization 82.54M
Operating cash flow -66.85M
ESG Scores unknown

Company description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio10.07
Working Capital-0.88
Return On Equity-1.15
Debt To Equity0.31
Fixed Asset Ratio0.01
Fixed Interest Cover-38.59

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.66M -1.42M 1.09M -194k
Total Cashflows From Investing Activities
Net Borrowings 1.36M 147k 147k -13.55M
Total Cash From Financing Activities 1.36M 29.52M 26.31M 112.07M
Change To Operating Activities 29k 8.29M -5.64M -1.21M
Issuance Of Stock 6.07M 13M 26.17M 125.62M
Net Income -3.48M -51.26M -19.1M -66.05M
Change In Cash -216k 10.22M 5.4M 63.07M
Effect Of Exchange Rate
Total Cash From Operating Activities -1.58M -19.3M -20.91M -48.99M
Depreciation 41k
Change To Account Receivables
Other Cashflows From Financing Activities -690k 16.52M
Change To Netincome 193k 25.09M 2.58M 16.88M
Capital Expenditures

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 553k 10.98M 10.98M 46.65M
Income Before Tax -3.48M -51.26M -19.1M -66.05M
Net Income -3.48M -51.26M -19.1M -66.05M
Selling General Administrative 2.63M 5.56M 7.78M 15.02M
Gross Profit -22.19M
Ebit -3.18M -27.75M -18.76M -61.67M
Operating Income -3.18M -27.75M -18.76M -61.67M
Interest Expense -131k -29k -164k -1.6M
Income Tax Expense
Total Revenue 375k
Cost Of Revenue 22.56M
Total Other Income ExpenseNet -68k -23.51M -342k -4.38M
Net Income From Continuing Ops -3.48M -51.26M -19.1M -66.05M
Net Income Applicable To Common Shares -3.48M -51.26M -19.1M -66.05M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 4.9M 11.1M 14.92M 26.18M
Total Stockholder Equity -4.71M -7k 2.57M 57.32M
Other Current Liabilities 21k 8.06M 1.19M 1.8M
Total Assets 191k 11.1M 17.49M 83.5M
Common Stock 3k 27k 54k 105k
Other Current Assets 140k 39k 187k
Retained Earnings -4.81M -56.06M -75.16M -141.21M
Treasury Stock
Cash 42k 10.26M 15.66M 78.73M
Total Current Liabilities 4.9M 10.78M 7.43M 8.29M
Other Stockholder Equity
Property, Plant, and Equipment 38k 39k
Total Current Assets 191k 11.1M 17.49M 83.46M
Net Tangible Assets -4.71M -7k 2.57M 57.32M
Net Receivables
Accounts Payable 2.22M 796k 1.89M 1.69M


Insider Transactions

Here are the insider transactions of stock shares related to Seelos Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
O CONNOR DANIEL JPurchase at price 0.61 per share.D2022-06-01Director16k
DALESANDRO MARGARET PH.DPurchase at price 0.60 per share.D2022-05-26Director35k
MEHRA RAJPurchase at price 0.85 per share.D2022-03-31Chief Executive Officer66.67k
GOLEMBIEWSKI MICHAEL JOSEPHStock Award(Grant) at price 0.90 per share.D2022-02-28Chief Financial Officer12.5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Seelos Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Seelos Therapeutics Inc

Here is the result of two systematic investment strategies applied to Seelos Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Seelos Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Seelos Therapeutics Inc:

Seelos Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 7.35% on the backtest period.

Performance at glance

Performance

7.35 %

Latent gain

166.47 $

Invested capital

2266.28 $

Annualized return

1.78 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Seelos Therapeutics Inc

This is the result of two momentum investment strategies applied to Seelos Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Seelos Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Seelos Therapeutics Inc:

Seelos Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 30.56% of return on Seelos Therapeutics Inc. That represents 1065.48$ of latent gain with 3486.54$ of employed capital.
  • The second momentum investment strategy would give 27.85% of return on Seelos Therapeutics Inc. That represents 903.79$ of latent gain with 3244.86$ of employed capital.
Performance at glance (1Q Momentum)

Performance

30.56 %

Latent gain

1065.48 $

Invested capital

3486.54 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

27.85 %

Latent gain

903.79 $

Invested capital

3244.86 $

Annualized return

7.61 %

Momentum equity curve on Seelos Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Seelos Therapeutics Inc:

Seelos Therapeutics Inc momentum equity

Note: the dividends potentially given by Seelos Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Seelos Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Seelos Therapeutics Inc since the beginning:

Seelos Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Seelos Therapeutics Inc

Buy the dip entry openings on Seelos Therapeutics Inc

Seelos Therapeutics Inc

The performance achieved by the robo-advisor on Seelos Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Seelos Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Seelos Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Seelos Therapeutics Inc

The following chart shows the result of the investment strategy applied to Seelos Therapeutics Inc:

Seelos Therapeutics Inc

Note: the dividends potentially given by Seelos Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Seelos Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Seelos Therapeutics Inc:

Seelos Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Seelos Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Seelos Therapeutics Inc.

Equity curve comparison on Seelos Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Seelos Therapeutics Inc investment strategy comparison

Employed capital comparison on Seelos Therapeutics Inc

Seelos Therapeutics Inc investment comparison

Performance comparison on Seelos Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 7.35% 166.47$ 2266.28$ 1.78%
Momentum 1 quarter 30.56% 1065.48$ 3486.54$ 7.84%
Momentum 2 quarters 27.85% 903.79$ 3244.86$ 7.61%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

1.78 %

Momentum 1Q

7.61 %

Momentum 2Q

7.61 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Seelos Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Seelos Therapeutics Inc

  • Most correlated stocks last 3 months

  • Seelos Therapeutics Inc
  • MULLEN GROUP LTD.
  • Park City Group Inc
  • HyreCar Inc
  • PENTAMASTER
  • Edesa Biotech Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • Y VENTURES

  • Note: The algorithm computes the probability of correlation between Seelos Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Seelos Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Seelos Therapeutics Inc
    Country United States
    City New York
    Address 300 Park Avenue
    Phone 646 293 2100
    Website seelostherapeutics.com
    FullTime employees 16
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker SEEL
    Market www.nasdaq.com

    Seelos Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown